A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
We want to find out how much of a medicine called PD-1 inhibitor is safe to use with two other medicines called talquetamab and teclistamab. We also want to know if it is okay to use the three medicines together.
We want to find out how much of a medicine called PD-1 inhibitor is safe to use with two other medicines called talquetamab and teclistamab. We also want to know if it is okay to use the three medicines together.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: